BioRestorative Therapies Files 2024 10-K
Ticker: BRTX · Form: 10-K · Filed: Mar 28, 2025 · CIK: 1505497
Sentiment: neutral
Topics: 10-K, financials, healthcare
Related Tickers: BRTX
TL;DR
BRTX filed its 2024 10-K. Financials look stable, but need deeper dive.
AI Summary
BioRestorative Therapies, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Stem Cell Assurance, Inc., is involved in miscellaneous health and allied services. The filing provides financial data for the fiscal years 2024, 2023, and 2022, including details on common stock, preferred stock, additional paid-in capital, and retained earnings.
Why It Matters
This 10-K filing provides a comprehensive overview of BioRestorative Therapies, Inc.'s financial performance and position for the fiscal year 2024, crucial for investors and stakeholders to assess the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a company in the health and allied services sector, BioRestorative Therapies, Inc. faces inherent risks related to clinical trials, regulatory approvals, and market adoption of its therapies.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for the 10-K)
- 2023 — Prior Fiscal Year End (Comparative financial data)
- 2022 — Prior Fiscal Year End (Comparative financial data)
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Filer of the 10-K
- Stem Cell Assurance, Inc. (company) — Former name of BioRestorative Therapies, Inc.
- 2024-12-31 (date) — Fiscal year end
- 2023-12-31 (date) — Prior fiscal year end
- 2022-12-31 (date) — Prior fiscal year end
FAQ
What is the primary business of BioRestorative Therapies, Inc.?
BioRestorative Therapies, Inc. is engaged in Services-Misc Health & Allied Services, NEC, with SIC code 8090.
When was the company formerly known as?
The company was formerly known as Stem Cell Assurance, Inc., with a name change date of 2010-11-10.
What is the filing date of this 10-K?
This 10-K filing was made on 2025-03-28.
What are the key financial components detailed in the filing for the fiscal year ending December 31, 2024?
The filing details components such as BRTX:SeriesBConvertiblePreferredStockMember, us-gaap:CommonStockMember, us-gaap:AdditionalPaidInCapitalMember, and us-gaap:RetainedEarningsMember for the fiscal year ending December 31, 2024.
What is the company's business address and phone number?
The business address is 40 Marcus Drive, Melville, NY 11747, and the business phone number is (631) 760-8100.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding BioRestorative Therapies, Inc. (BRTX).